Goldenberg A, Kelsen D, Benedetto P
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Oncology. 1988;45(4):273-5. doi: 10.1159/000226621.
A Phase II trial of mitoxantrone was performed in patients with advanced adenocarcinoma of the stomach. All patients had measurable or evaluable disease, and none had received prior chemotherapy. Mitoxantrone was administered intravenously at a dose of 14 mg/m2 every 3 weeks. The major toxicity seen was myelosuppression. The drug was, in general, well tolerated. No major objective responses were seen. We conclude that mitoxantrone has less than 20% activity in this patient population. No further studies are planned.
对晚期胃癌患者进行了米托蒽醌的II期试验。所有患者均有可测量或可评估的疾病，且均未接受过先前的化疗。米托蒽醌以每3周14mg/m²的剂量静脉给药。观察到的主要毒性是骨髓抑制。总体而言，该药物耐受性良好。未观察到主要的客观反应。我们得出结论，米托蒽醌在该患者群体中的活性低于20%。未计划进一步的研究。
